R
Rita Chiari
Researcher at University of Perugia
Publications - 187
Citations - 7144
Rita Chiari is an academic researcher from University of Perugia. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 33, co-authored 168 publications receiving 4646 citations. Previous affiliations of Rita Chiari include Université catholique de Louvain.
Papers
More filters
Journal ArticleDOI
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria,Daniel Shao-Weng Tan,Rita Chiari,Yi-Long Wu,Luis Paz-Ares,Juergen Wolf,Sarayut Lucien Geater,Sergey Orlov,Diego Cortinovis,Chong-Jen Yu,Maximillian Hochmair,Alexis B. Cortot,Chun-Ming Tsai,Denis Moro-Sibilot,Rosario Garcia Campelo,Tracey McCulloch,Paramita Sen,Margaret Dugan,Serafino Pantano,Fabrice Branle,Cristian Massacesi,Gilberto de Castro +21 more
TL;DR: First-line ceritinib showed a statistically significant and clinically meaningful improvement in progression-free survival versus chemotherapy in patients with advanced ALK-rearranged NSCLC.
Journal ArticleDOI
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin Solomon,Benjamin Besse,Benjamin Besse,Todd M. Bauer,Enriqueta Felip,Ross A. Soo,D. Ross Camidge,Rita Chiari,Alessandra Bearz,Chia-Chi Lin,Shirish M. Gadgeel,Gregory J. Riely,Eng Huat Tan,Takashi Seto,Leonard P. James,Jill S. Clancy,Antonello Abbattista,Jean-Francois Martini,Joseph Chen,Gerson Peltz,Holger Thurm,Sai-Hong Ignatius Ou,Alice T. Shaw +22 more
TL;DR: Overall and intracranial antitumour activity of lorlatinib in patients with ALK-positive, advanced non-small-cell lung cancer and safety data for all treated patients (EXP1-6) are presented.
Journal ArticleDOI
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Hossein Borghaei,Scott N. Gettinger,Everett E. Vokes,Laura Q.M. Chow,Marco Angelo Burgio,Javier de Castro Carpeño,Adam Pluzanski,Oscar Arrieta,Osvaldo Arén Frontera,Rita Chiari,Charles Butts,Joanna Wojcik-Tomaszewska,Bruno Coudert,Marina Chiara Garassino,Neal Ready,Enriqueta Felip,Miriam Alonso Garcia,David M. Waterhouse,Manuel Domine,Fabrice Barlesi,Scott J. Antonia,Markus Wohlleber,David E. Gerber,Grzegorz Czyzewicz,David R. Spigel,Lucio Crinò,Wilfried Enst Erich Eberhardt,Ang Li,S. Marimuthu,Julie R. Brahmer +29 more
TL;DR: In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in o... as mentioned in this paper, and showed an improved lung cancer survival.
Journal ArticleDOI
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Alessio Cortellini,Melissa Bersanelli,Sebastiano Buti,Katia Cannita,Daniele Santini,Fabiana Perrone,Raffaele Giusti,Marcello Tiseo,Maria Michiara,Pietro Di Marino,Nicola Tinari,Michele De Tursi,Federica Zoratto,Enzo Veltri,Riccardo Marconcini,Francesco Malorgio,Marco Russano,Cecilia Anesi,Tea Zeppola,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Gian Carlo Antonini Cappellini,Federica De Galitiis,Maria Giuseppa Vitale,Francesca Rastelli,Federica Pergolesi,Rossana Berardi,Silvia Rinaldi,Marianna Tudini,Rosa Rita Silva,Annagrazia Pireddu,Francesco Atzori,Rita Chiari,Biagio Ricciuti,Andrea De Giglio,Daniela Iacono,Alain Gelibter,Mario Occhipinti,Alessandro Parisi,Giampiero Porzio,Maria Concetta Fargnoli,Paolo A. Ascierto,Corrado Ficorella,Clara Natoli +44 more
TL;DR: Overweight could be considered a tumorigenic immune-dysfunction that could be effectively reversed by ICIs and BMI could be a useful predictive tool in clinical practice and a stratification factor in prospective clinical trials with ICIs.
Journal ArticleDOI
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Alice T. Shaw,Benjamin Solomon,Benjamin Besse,Todd M. Bauer,Chia-Chi Lin,Ross A. Soo,Gregory J. Riely,Sai-Hong Ignatius Ou,Jill S. Clancy,Sherry Li,Antonello Abbattista,Holger Thurm,Miyako Satouchi,D. Ross Camidge,Steven Kao,Rita Chiari,Shirish M. Gadgeel,Enriqueta Felip,Jean-Francois Martini +18 more
TL;DR: Tumor genotyping for ALK mutations after failure of a second-generation TKI may identify patients who are more likely to derive clinical benefit from lorlatinib.